DUBLIN--(BUSINESS WIRE)--Mallinckrodt plc (NYSE: MNK) will report third quarter results on August 7, 2014. The company will hold a conference call for investors beginning at 8:30am U.S. Eastern Time. The call can be accessed in three ways:
- At the Mallinckrodt website: http://mallinckrodt.com/investor_relations.aspx
- By telephone: For both “listen-only” participants and those who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. (844) 867-9755 For participants outside the U.S., the dial-in number is (901) 300-3301. The access code for all callers is #74207880
- Through an audio replay: A replay of the call will be available beginning Thursday afternoon, August 7, 2014, and ending at 12:59pm/ U.S. Eastern Time on August 14, 2014. The dial-in numbers for U.S. participants are (800) 585-8367 or (855) 859-2056.
- For participants outside the U.S., the replay dial-in number is (404) 537-3406. The replay access code for all callers is #74207880
Mallinckrodt is a global specialty pharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company’s core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company’s Specialty Pharmaceuticals segment includes branded and specialty generic drugs and active pharmaceutical ingredients, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt has approximately 5,500 employees worldwide and a commercial presence in approximately 65 countries. The company’s fiscal 2013 revenue totaled $2.2 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.